Outcome of February 2019 PTAC meeting

Kia ora Gill,

I wanted to touch base to let you know that we have published the advice and recommendations from the February 2019 Pharmacology and Therapeutics Advisory Committee (PTAC) meeting.

As you know, a number of medicines for rare disorders were considered by our expert clinical advisors at this meeting. These were initially assessed by our Rare Disorders Subcommittee in November 2018.

None

I can assure you that we are still taking these funding applications through our funding process.

Recommendations from clinical advisors are one just one input to PHARMAC’s decision-making. We have also compared and ranked these funding applications against other funding applications we have received. We do not generally undertake further assessment of funding applications that have been recommended for decline. We will, however, consider any new evidence and information that we may receive.

We cannot give a timeframe for if, or when, we may make a funding decision about any of these funding applications. We will continue to stay in contact with you.

Applications with a changed funding priority

Recommended for funding with a high priority

Recommended for funding with a medium priority

Recommendation deferred

Recommended for decline

You may also be interested to know that we have recently called for more funding applications for medicines for rare disorders. These applications will be assessed by our Rare Disorders Subcommittee in September 2019.

I hope this information is helpful for you and your networks.

Ngā mihi nui

Alison

Alison Hill| Director Engagement and Implementation